atorvastatin has been researched along with ST Elevated Myocardial Infarction in 18 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 7 (38.89) | 24.3611 |
| 2020's | 11 (61.11) | 2.80 |
| Authors | Studies |
|---|---|
| Abusoglu, G; Abusoglu, S; Erdem, K; Eryavuz Onmaz, D; Sivrikaya, A; Unlu, A; Yaglioglu, H | 1 |
| Chen, W; Fan, Z; Han, Z; Huang, C; Liu, J | 1 |
| Geiling, JA; Haxhikadrija, P; Lauer, B; Makhmudova, U; Maloku, A; Möbius-Winkler, S; Otto, S; Römer, R; Samadifar, B; Schulze, PC; Weingärtner, O | 1 |
| Abdullaev, DEO; Gavrilko, AD; Krasheninin, DV; Kuslivyi, AM; Mezhonov, EM; Shalaev, SV; Shermuk, AA; Vyalkina, YA | 1 |
| Avdeeva, IV; Borisova, NA; Khromova, AA; Korenkova, KN; Kvasova, OG; Oleynikov, VE; Polezhaeva, KN; Salyamova, LI | 1 |
| Dong, H; Hu, X; Li, G; Liang, W; Lin, Y; Lu, H; Wang, W; Yu, B; Zhang, H; Zhou, L; Zhou, Y | 1 |
| Ito, Y; Kasahara, M; Kasama, S; Kurabayashi, M; Nakata, T; Suzuki, S; Takahashi, S; Toyama, T | 1 |
| Cao, M; He, W; Li, Z | 1 |
| Gao, RL; Geng, YJ; Huang, J; Huang, PS; Li, N; Lu, MJ; Qian, HY; Qian, J; Shen, R; Song, L; Tian, XQ; Wang, H; Wu, WC; Wu, Y; Xiong, YY; Xu, J; Xu, JY; Yang, YJ; Zhang, J; Zhao, SH | 1 |
| Chen, H; Chen, J; Dai, Y; Duan, C; He, P; Huang, J; Huang, Z; Liu, Y; Shao, S; Tan, N; Xue, L; Yu, D; Zeng, L | 1 |
| Chen, Y; Hu, M; Wang, Y; Zhang, L | 1 |
| Alexander, JH; Armaganijan, LV; Baldissera, F; Barbosa, LM; Beraldo de Andrade, P; Berwanger, O; Bienert, IRC; Borges de Oliveira, JA; Bosso, CE; Cavalcanti, AB; Dall Orto, FTC; Damiani, LP; de Barros E Silva, PGM; Egydio, FM; Giraldez, RRCV; Granger, CB; Guimarães, HP; Jesuíno, IA; Kalil, RAK; Laranjeira, LN; Lopes, RD; Mangione, JA; Mattos, LA; Nascimento, BR; Pereira, SB; Polanczyk, CA; Rech, RL; Santos, LM; Santos, RHN; Santucci, EV; Sousa, ACS; Sousa, AGMR; Sousa, JEMR; Sposito, AC | 1 |
| Barmenkova, YA; Dushina, EV; Lukyanova, MV; Oleynikov, VE; Salyamova, LI | 1 |
| Cheng, X; Liu, Q; Wang, Y | 1 |
| Aquino, M; Baber, U; Barman, N; Camaj, A; Chandrasekhar, J; Claessen, B; Dangas, G; Faggioni, M; Farhan, S; Guedeney, P; Kalkman, DN; Kini, A; Kovacic, JC; Mehran, R; Moreno, P; Shah, S; Sharma, S; Sorrentino, S; Sweeny, J; Vijay, P; Vogel, B | 1 |
| Almeida-Gutierrez, E; Alonso-Bravo, RM; Borrayo-Sanchez, G; García-Méndez, RC; Isordia-Salas, I; Ortega-Ramirez, JA; Palomo-Villada, JA; Rosas-Peralta, M; Sánchez-Díaz, JS; Serrano-Cuevas, L | 1 |
| De Servi, S; Leoncini, M; Toso, A | 1 |
| Li, K; Liu, Y; Wang, P; Xu, L; Xu, X; Yang, X; Yang, Z | 1 |
5 trial(s) available for atorvastatin and ST Elevated Myocardial Infarction
| Article | Year |
|---|---|
Effects of different doses of atorvastatin, rosuvastatin, and simvastatin on elderly patients with ST-elevation acute myocardial infarction (AMI) after percutaneous coronary intervention (PCI).
Topics: Aged; Aged, 80 and over; Alanine Transaminase; Atorvastatin; Cholesterol; Coronary Angiography; Creatine Kinase, MB Form; Double-Blind Method; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Natriuretic Peptide, Brain; Percutaneous Coronary Intervention; Rosuvastatin Calcium; Simvastatin; ST Elevation Myocardial Infarction; Troponin I | 2020 |
Strengthening effects of bone marrow mononuclear cells with intensive atorvastatin in acute myocardial infarction.
Topics: Adult; Aged; Atorvastatin; Beijing; Bone Marrow Transplantation; Combined Modality Therapy; Double-Blind Method; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Recovery of Function; ST Elevation Myocardial Infarction; Stroke Volume; Time Factors; Transplantation, Autologous; Treatment Outcome; Ventricular Function, Left; Ventricular Remodeling | 2020 |
Effect of Loading Dose of Atorvastatin Prior to Planned Percutaneous Coronary Intervention on Major Adverse Cardiovascular Events in Acute Coronary Syndrome: The SECURE-PCI Randomized Clinical Trial.
Topics: Acute Coronary Syndrome; Aged; Atorvastatin; Cardiovascular Diseases; Double-Blind Method; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Percutaneous Coronary Intervention; Preoperative Care; ST Elevation Myocardial Infarction | 2018 |
Reduction of No Reflow with a Loading Dose of Atorvastatin before Primary Angioplasty in Patients with Acute ST Myocardial Infarction.
Topics: Adult; Aged; Angioplasty; Atorvastatin; C-Reactive Protein; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; No-Reflow Phenomenon; Percutaneous Coronary Intervention; Preliminary Data; ST Elevation Myocardial Infarction; Survival Rate; Treatment Outcome | 2018 |
Intensive atorvastatin improves endothelial function and decreases ADP-induced platelet aggregation in patients with STEMI undergoing primary PCI: A single-center randomized controlled trial.
Topics: Adenosine Diphosphate; Aged; Atorvastatin; Endothelium, Vascular; Female; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation; Prospective Studies; Single-Blind Method; ST Elevation Myocardial Infarction; Treatment Outcome | 2016 |
13 other study(ies) available for atorvastatin and ST Elevated Myocardial Infarction
| Article | Year |
|---|---|
New steps in acute coronary syndrome and antihyperlipidemic treatment: Determination of statins and metabolites by liquid chromatography tandem mass spectrometry.
Topics: Acute Coronary Syndrome; Atorvastatin; Chromatography, Liquid; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Non-ST Elevated Myocardial Infarction; Rosuvastatin Calcium; ST Elevation Myocardial Infarction; Tandem Mass Spectrometry | 2022 |
Enhanced-Dose Statins for ST-Segment Elevation Myocardial Infarction Patients after Emergency Percutaneous Coronary Intervention.
Topics: Atorvastatin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Percutaneous Coronary Intervention; ST Elevation Myocardial Infarction; Stroke Volume; Treatment Outcome; Ventricular Function, Left | 2022 |
Intensive lipid-lowering therapy for early achievement of guideline-recommended LDL-cholesterol levels in patients with ST-elevation myocardial infarction ("Jena auf Ziel").
Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; PCSK9 Inhibitors; Proprotein Convertase 9; Prospective Studies; ST Elevation Myocardial Infarction; Treatment Outcome | 2023 |
[Influence of Loading Dose Of Atorvastatin on the Risk of Contrast-Induced Nephropathy in Patients With ST-Segment Elevation Myocardial Infarction].
Topics: Atorvastatin; Contrast Media; Creatinine; Humans; Kidney Diseases; Retrospective Studies; ST Elevation Myocardial Infarction | 2023 |
[Vasoprotective effect of effective lipid-lowering therapy in patients with
Topics: Atorvastatin; Carotid Intima-Media Thickness; Cholesterol, LDL; Humans; ST Elevation Myocardial Infarction; Treatment Outcome | 2023 |
Effects of atorvastatin and rosuvastatin on dysfunctional coronary circulation in patients with ST-segment elevation myocardial infarction.
Topics: Atorvastatin; Coronary Angiography; Coronary Circulation; Humans; Microcirculation; Myocardial Infarction; No-Reflow Phenomenon; Percutaneous Coronary Intervention; Retrospective Studies; Rosuvastatin Calcium; ST Elevation Myocardial Infarction; Treatment Outcome | 2023 |
Assessment of therapeutic effects of statin on cardiac sympathetic nerve activity after reperfusion therapy in patients with first ST-segment elevation myocardial infarction and normal low-density lipoprotein cholesterol.
Topics: 3-Iodobenzylguanidine; Aged; Angioplasty, Balloon, Coronary; Atorvastatin; Cholesterol, LDL; Echocardiography; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Peptide Fragments; Procollagen; Quinolines; Radiopharmaceuticals; Retrospective Studies; Rosuvastatin Calcium; ST Elevation Myocardial Infarction; Stroke Volume; Sympathetic Nervous System; Treatment Outcome | 2021 |
Comparison of the preventive efficacy of rosuvastatin versus atorvastatin in post-contrast acute kidney injury in patients with ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention.
Topics: Acute Kidney Injury; Aged; Atorvastatin; Biomarkers; Contrast Media; Creatinine; Female; Hospital Mortality; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Percutaneous Coronary Intervention; Risk Factors; Rosuvastatin Calcium; ST Elevation Myocardial Infarction; Time Factors; Treatment Outcome; Up-Regulation | 2020 |
Effects of atorvastatin and ticagrelor combination therapy on renal function and the levels of suppression of tumorigenicity 2 and interleukin-33 in patients with ST-segment elevation myocardial infarction.
Topics: Atorvastatin; Humans; Interleukin-1 Receptor-Like 1 Protein; Interleukin-33; Percutaneous Coronary Intervention; Retrospective Studies; ST Elevation Myocardial Infarction; Ticagrelor; Treatment Outcome | 2020 |
[The Impact of Effective Therapy With Atorvastatin on the Dynamics of Parameters of Electrical Instability in Patients with ST-Elevation Myocardial Infarction].
Topics: Atorvastatin; Cholesterol, LDL; Electrocardiography; Humans; ST Elevation Myocardial Infarction | 2018 |
The functional effect of atorvastatin dose-dependent via inflammation factors on acute ST segment elevation myocardial infarction after emergency percutaneous coronary intervention.
Topics: Adult; Aged; Anti-Inflammatory Agents; Atorvastatin; Biomarkers; C-Reactive Protein; Cholesterol, LDL; Dose-Response Relationship, Drug; Emergencies; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation Mediators; Male; Middle Aged; Percutaneous Coronary Intervention; Quality of Life; Recurrence; Risk Factors; ST Elevation Myocardial Infarction; Time Factors; Treatment Outcome | 2019 |
Temporal trends, determinants, and impact of high-intensity statin prescriptions after percutaneous coronary intervention: Results from a large single-center prospective registry.
Topics: Adrenergic beta-Antagonists; Age Factors; Aged; Angina, Unstable; Atherosclerosis; Atorvastatin; Drug Prescriptions; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kaplan-Meier Estimate; Male; Middle Aged; Multivariate Analysis; Myocardial Infarction; Non-ST Elevated Myocardial Infarction; Odds Ratio; Percutaneous Coronary Intervention; Practice Guidelines as Topic; Prospective Studies; Registries; Rosuvastatin Calcium; Secondary Prevention; Simvastatin; ST Elevation Myocardial Infarction; Tertiary Care Centers; Time Factors | 2019 |
Statins and myocardial infarction: from secondary 'prevention' to early 'treatment'.
Topics: Atorvastatin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Myocardial Infarction; Percutaneous Coronary Intervention; Secondary Prevention; ST Elevation Myocardial Infarction | 2019 |